2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Molecular Testing, Clinical Procedures, Treatment Considerations, Combination Therapy, Supportive Care, Biological Therapies, Non-Biological Therapies, Chemotherapy, Adverse Events, Artificial Intelligence (AI), Machine Learning, Biological Processes, Immune Mechanism, Molecular Biology, Clinical Practice (Health Services and Quality), Patient Safety, Practice Models, Value, Diseases, Bleeding and Clotting, Immunology, Infectious Diseases, Fungal, Lymphoid Malignancies, Lymphoid Leukemias, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, ALL, Research, AML, Translational Research, MDS, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

1599 A novel dynamic predictive model and risk factor analysis for early treatment failure in unfit AML treated with venetoclax plus hypomethylating agents

Kaihang Shi, N/A, Xueyan Sun, MD2, Liang Huang, MD3, Gaoxiang Wang, MD4
1 Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
2 Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
3 Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
4 Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
Background: Most existing prognostic models for acute myeloid leukemia (AML) patients treated with venetoclax combined with hypomethylating agents (HMAs) primarily focus on overall survival (OS). Although achieving an early response is crucial for improving long-term survival, clinical tools that accurately evaluate the risk of early resistance remain lacking. Therefore, this study aimed to investigate the risk factors associated with early induction failure of the venetoclax plus HMAs regimen and to develop a novel efficacy prediction model. Methods: A total of 167 AML patients who received induction therapy with venetoclax and HMAs at Tongji Hospital between 2023 and 2026 were retrospectively included. The primary endpoint was the treatment response at 1 month post-induction (CR/CRi vs. NR/PR). Independent risk factors were identified using multivariable logistic regression analysis to construct a weighted efficacy scoring model. Model performance was evaluated using receiver operating characteristic (ROC) curves, calibration curves, and decision curve analysis (DCA). Furthermore, time-dependent ROC and Cox proportional hazards regression were employed to validate its predictive performance for event-free survival (EFS). Results: The median age of the 167 patients was 65 years. Among them, 105 (62.9%) achieved CR/CRi, while 62 (37.1%) experienced early treatment failure. Multivariable analysis identified four independent risk factors, which were assigned corresponding scores based on their regression coefficients: IDH1/2 wild-type (2 points), baseline platelet count ≤ 50 × 10?/L (1 point), chromosomal abnormalities (1 point), and nadir white blood cell (WBC) count > 1.0 × 10?/L during induction (1 point). Based on the total score (0-5 points), patients were stratified into low-risk (0-2 points), intermediate-risk (3 points), and high-risk (4-5 points) groups. The early induction failure rates across the three groups were 17.9%, 30.8%, and 61.0%, respectively (P < 0.001), and the 1-year EFS rates were 51.7%, 34.8%, and 15.7%, respectively (P < 0.001). The area under the curve (AUC) for predicting early efficacy was 0.731, and the AUC for predicting 1-year EFS was 0.720. The model demonstrated excellent calibration and significant net clinical benefit. Conclusions: This study is the first to construct an early efficacy scoring model specifically for AML patients undergoing induction therapy with venetoclax and HMAs, enabling the precise identification of populations at high risk for early treatment failure. Furthermore, we confirmed that early treatment response is highly correlated with long-term prognosis. This scoring system provides a reliable basis for clinicians to adjust intervention strategies promptly and formulate personalized salvage treatment plans.
Kaihang Shi, N/A: No relevant conflicts of interest to declare.